awmsg logo



valganciclovir (Valcyte®)


Reference No. 812

Publication date:
07/09/2011


Appraisal information

valganciclovir (Valcyte®) 450 mg film-coated tablet


Company: Roche Products Ltd
BNF category: Infections
NMG meeting date: 11/05/2011
AWMSG meeting date: 15/06/2011
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0611
Ministerial ratification: 01/09/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Valganciclovir (Valcyte®) tablets are recommended as an option for use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor. AWMSG is of the opinion that valganciclovir (Valcyte®) tablets are not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download